AIM ImmunoTech 
Welcome,         Profile    Billing    Logout  
 3 Products   51 Diseases  3 Products   4 Trials   426 News 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ampligen (rintatolimod) / AIM ImmunoTech
NCT05592418: Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

Completed
2
80
US
Rintatolimod, Ampligen, poly I : poly C12U, Rintatolimod (poly I : poly C12U), Placebo / Normal Saline
AIM ImmunoTech Inc., Amarex Clinical Research
Post COVID-19 Condition, Long COVID
11/23
11/23
NCI-2019-01192, NCT03899987: Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Recruiting
2
30
US
EC Aspirin, Acetylsalicylic Acid, ASA, Aspergum, aspirin, Ecotrin, Empirin, Entericin, Extren, Measurin, Enteric-coated aspirin, Radical Prostatectomy, Prostatovesiculectomy, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon, Rintatolimod, Ampligen, Atvogen
Roswell Park Cancer Institute, AIM ImmunoTech Inc.
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
11/26
11/26
NCT04093323: Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Terminated
2
1
US
Alpha-type-1 Polarized Dendritic Cells, alphaDC1, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, PD-1 Ligand Inhibitor, PD-1 Ligands Inhibitor, PD1 Inhibitor, PD-1 Inhibitor, Programmed Cell Death Protein 1 Inhibitor, Protein PD-1 Inhibitor, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon, Rintatolimod, Ampligen, Atvogen
Roswell Park Cancer Institute, National Cancer Institute (NCI)
HLA-A2 Positive Cells Present, Refractory Melanoma
04/25
06/25
NCT05494697: Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Hourglass Jan 2024 - Dec 2024 : Data readout for locally advanced pancreatic adenocarcinoma
Suspended
2
90
US
Rintatolimod, Ampligen, poly I : poly C12U
AIM ImmunoTech Inc., Amarex Clinical Research
Pancreatic Cancer
09/28
10/28
NCT04379518: Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Suspended
1/2
64
US
Best Practice, standard of care, standard therapy, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon, Rintatolimod, Ampligen, Atvogen
Roswell Park Cancer Institute, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
11/23
11/23
NCT03734692: Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Protocol-planned interim results readout for advanced recurrent ovarian cancer
Hourglass Nov 2023 - Nov 2023 : Data from P2 trial for recurrent platinum-sensitive ovarian cancer at SITC 2023
Checkmark Results from trial in combination with Ampligen
Mar 2022 - Mar 2022: Results from trial in combination with Ampligen
Active, not recruiting
1/2
24
US
Rintatolimod, Ampligen, Pembrolizumab, Keytruda, Cisplatin, Platinol
Robert Edwards, AIM ImmunoTech Inc., Merck Sharp & Dohme LLC
Ovarian Cancer Recurrent
07/24
01/27
DURIPANC, NCT05927142: Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

Recruiting
1/2
43
Europe
Durvalumab, Imfinzi, MEDI4736, Rintatolimod, Ampligen
Joachim Aerts, MD PhD, AIM ImmunoTech Inc., AstraZeneca
Metastatic Pancreatic Cancer
04/26
04/27
NCT05756166: Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Terminated
1/2
5
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Interferon Alpha-2, Alpha-2-Interferon, Alpha-2a Interferon, IFN-Alpha-2, IFN-AlphaA, IFNA2, IFNA2 Protein, Interferon Alpha 2, Interferon Alpha 2a, Interferon Alpha 2b, Interferon Alpha A, Interferon Alpha-A, LeIF A, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Rintatolimod, Ampligen, Atvogen
Roswell Park Cancer Institute, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
04/25
06/25
NCT02432378: Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

Terminated
1/2
25
US
Cisplatin + celecoxib + DC vaccine, Cisplatin + CKM + Celecoxib + DC Vaccine
Roswell Park Cancer Institute, AIM ImmunoTech Inc., National Cancer Institute (NCI), University of Pittsburgh
Cancer of Ovary, Cancer of the Ovary, Neoplasms, Ovarian, Ovarian Cancer, Ovary Cancer, Ovary Neoplasms
06/25
06/25
NCT03599453: Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Completed
1
8
US
Biopsy, Chemokine Modulation Therapy, Celecoxib, Celebrex, YM 177, Benzenesulfonamide, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Intron A, recombinant interferon alfa-2b, Recombinant Interferon Alfa-2b, Sch, Rintatolimod, 38640-92-5, 616524, Ampligen, Ampligen, Atvogen, Poly(I).Poly(c12,U), Poly(Inosinic Acid) Poly(Cytidylic(12), Uridylic)Acid, RINTATOLIMOD, Rintatolimod, Pembrolizumab, Immunoglobulin G4,Keytruda, Lambrolizumab
Roswell Park Cancer Institute, AIM ImmunoTech Inc.
Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative, Anatomic Stage IV Breast Cancer AJCC, Progesterone Receptor Negative
09/20
03/23
NCT04081389: Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Completed
1
9
US
Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon, Rintatolimod, Ampligen, Atvogen
Roswell Park Cancer Institute, National Center for Advancing Translational Sciences (NCATS)
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
05/22
02/23
NCT00215813: Ampligen in Chronic Fatigue Syndrome

Available
N/A
US
Poly I: Poly C12U (Rintatolimod), Ampligen, Rintatolimod
AIM ImmunoTech Inc.
Chronic Fatigue Syndrome
 
 
Alferon LDO (low dose interferon alfa-n3) / AIM ImmunoTech
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ampligen (rintatolimod) / AIM ImmunoTech
NCT05592418: Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

Completed
2
80
US
Rintatolimod, Ampligen, poly I : poly C12U, Rintatolimod (poly I : poly C12U), Placebo / Normal Saline
AIM ImmunoTech Inc., Amarex Clinical Research
Post COVID-19 Condition, Long COVID
11/23
11/23
NCI-2019-01192, NCT03899987: Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Recruiting
2
30
US
EC Aspirin, Acetylsalicylic Acid, ASA, Aspergum, aspirin, Ecotrin, Empirin, Entericin, Extren, Measurin, Enteric-coated aspirin, Radical Prostatectomy, Prostatovesiculectomy, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon, Rintatolimod, Ampligen, Atvogen
Roswell Park Cancer Institute, AIM ImmunoTech Inc.
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
11/26
11/26
NCT04093323: Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Terminated
2
1
US
Alpha-type-1 Polarized Dendritic Cells, alphaDC1, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, PD-1 Ligand Inhibitor, PD-1 Ligands Inhibitor, PD1 Inhibitor, PD-1 Inhibitor, Programmed Cell Death Protein 1 Inhibitor, Protein PD-1 Inhibitor, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon, Rintatolimod, Ampligen, Atvogen
Roswell Park Cancer Institute, National Cancer Institute (NCI)
HLA-A2 Positive Cells Present, Refractory Melanoma
04/25
06/25
NCT05494697: Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Hourglass Jan 2024 - Dec 2024 : Data readout for locally advanced pancreatic adenocarcinoma
Suspended
2
90
US
Rintatolimod, Ampligen, poly I : poly C12U
AIM ImmunoTech Inc., Amarex Clinical Research
Pancreatic Cancer
09/28
10/28
NCT04379518: Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

Suspended
1/2
64
US
Best Practice, standard of care, standard therapy, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon, Rintatolimod, Ampligen, Atvogen
Roswell Park Cancer Institute, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
11/23
11/23
NCT03734692: Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Protocol-planned interim results readout for advanced recurrent ovarian cancer
Hourglass Nov 2023 - Nov 2023 : Data from P2 trial for recurrent platinum-sensitive ovarian cancer at SITC 2023
Checkmark Results from trial in combination with Ampligen
Mar 2022 - Mar 2022: Results from trial in combination with Ampligen
Active, not recruiting
1/2
24
US
Rintatolimod, Ampligen, Pembrolizumab, Keytruda, Cisplatin, Platinol
Robert Edwards, AIM ImmunoTech Inc., Merck Sharp & Dohme LLC
Ovarian Cancer Recurrent
07/24
01/27
DURIPANC, NCT05927142: Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy

Recruiting
1/2
43
Europe
Durvalumab, Imfinzi, MEDI4736, Rintatolimod, Ampligen
Joachim Aerts, MD PhD, AIM ImmunoTech Inc., AstraZeneca
Metastatic Pancreatic Cancer
04/26
04/27
NCT05756166: Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Terminated
1/2
5
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Interferon Alpha-2, Alpha-2-Interferon, Alpha-2a Interferon, IFN-Alpha-2, IFN-AlphaA, IFNA2, IFNA2 Protein, Interferon Alpha 2, Interferon Alpha 2a, Interferon Alpha 2b, Interferon Alpha A, Interferon Alpha-A, LeIF A, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Rintatolimod, Ampligen, Atvogen
Roswell Park Cancer Institute, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
04/25
06/25
NCT02432378: Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

Terminated
1/2
25
US
Cisplatin + celecoxib + DC vaccine, Cisplatin + CKM + Celecoxib + DC Vaccine
Roswell Park Cancer Institute, AIM ImmunoTech Inc., National Cancer Institute (NCI), University of Pittsburgh
Cancer of Ovary, Cancer of the Ovary, Neoplasms, Ovarian, Ovarian Cancer, Ovary Cancer, Ovary Neoplasms
06/25
06/25
NCT03599453: Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Completed
1
8
US
Biopsy, Chemokine Modulation Therapy, Celecoxib, Celebrex, YM 177, Benzenesulfonamide, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Intron A, recombinant interferon alfa-2b, Recombinant Interferon Alfa-2b, Sch, Rintatolimod, 38640-92-5, 616524, Ampligen, Ampligen, Atvogen, Poly(I).Poly(c12,U), Poly(Inosinic Acid) Poly(Cytidylic(12), Uridylic)Acid, RINTATOLIMOD, Rintatolimod, Pembrolizumab, Immunoglobulin G4,Keytruda, Lambrolizumab
Roswell Park Cancer Institute, AIM ImmunoTech Inc.
Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative, Anatomic Stage IV Breast Cancer AJCC, Progesterone Receptor Negative
09/20
03/23
NCT04081389: Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Completed
1
9
US
Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon, Rintatolimod, Ampligen, Atvogen
Roswell Park Cancer Institute, National Center for Advancing Translational Sciences (NCATS)
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
05/22
02/23
NCT00215813: Ampligen in Chronic Fatigue Syndrome

Available
N/A
US
Poly I: Poly C12U (Rintatolimod), Ampligen, Rintatolimod
AIM ImmunoTech Inc.
Chronic Fatigue Syndrome
 
 
Alferon LDO (low dose interferon alfa-n3) / AIM ImmunoTech
No trials found

Download Options